Leerink Partners Reiterates Buy Rating on ALT
Leerink Partners reiterated its buy rating on ALT, setting a $10 price target, a 238.60% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on ALT, setting a price target of $10 on June 22, 2026.
- Leerink Partners's $10 price target implies 238.60% upside from Altimmune, Inc.'s ($ALT) current $2.95 share price.
- ALT shares traded at $2.95 on Monday, with institutional investors like BlackRock and State Street increasing their holdings.
- Insiders including John Gill and Diane Jorkasky bought 48,800 shares each on May 1, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Leerink Partners reiterated its buy rating on ALT, setting a price target of $10. This comes as ALT shares traded at $2.95 on Monday. Analyst Thomas Smith's reiteration suggests confidence in the stock's potential for growth.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ALT
BlackRock, Inc. increased its holdings in ALT by 3,090,979 shares, bringing its total to 12,795,277 shares valued at approximately $39.4 million, a 31.9% increase. State Street Corp also grew its position by 2,025,847 shares, ending with 7,145,550 shares worth about $22 million, marking a 39.6% increase. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions in ALT, with holdings of 5,658,049 and 5,382,002 shares, valued at $17.4 million and $16.6 million respectively. Marshall Wace, LLP increased its stake by 3,095,124 shares to 4,017,901 shares, a 335.4% increase, and Millennium Management LLC significantly boosted its holdings by 3,050,808 shares to a total of 3,258,191 shares, a 1471.1% increase.
Altimmune, Inc. Stock Down 5.0%
Shares of ALT traded at $2.95 on Monday. The stock has experienced various institutional interest, with major investors increasing their stakes, indicating positive sentiment. Although specific financial metrics such as market cap or P/E ratio are not available, the stock's recent trading activity reflects ongoing interest from both institutional and insider investors.
$ALT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Altimmune, Inc.
On May 1, 2026, several insiders, including John Gill, Diane Jorkasky, Teri Lawver, Wayne Pisano, Philip Hodges, and Catherine Sohn, each purchased 48,800 shares of ALT. These transactions were not conducted under Rule 10b5-1 plans, signaling direct interest from these insiders.
Analysts Set New Price Targets
On June 22, 2026, Leerink Partners reiterated its buy rating on ALT with a $10 price target. Earlier, on May 18, 2026, HC Wainwright & Co. maintained its buy rating with a $20 target. Citizens also maintained a buy rating on May 14, 2026, with an $11 target. These consistent buy ratings from multiple firms suggest a positive outlook for ALT.
Bottom Line
Leerink Partners' reiteration of its buy rating on ALT with a $10 price target highlights the firm's confidence in the stock. Institutional investors have shown strong interest, with significant increases in holdings. Insider buying further supports positive sentiment, though investors should remember that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.
Get Altimmune, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.